Pulmonx Target of Unusually Large Options Trading (NASDAQ:LUNG)

Pulmonx Corporation (NASDAQ:LUNG) was the target of unusually large options trading activity on Thursday. Traders bought 3,491 put options on the stock. This is an increase of approximately 1,895% compared to the typical daily volume of 175 put options.

Wall Street Analysts Forecast Growth

LUNG has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a report on Monday, July 13th. D. Boral Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research note on Thursday, April 30th. Finally, Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.58.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Pulmonx during the 1st quarter valued at about $26,000. Cerity Partners LLC bought a new position in shares of Pulmonx in the 4th quarter worth approximately $27,000. Opal Capital LLC purchased a new position in shares of Pulmonx in the fourth quarter worth approximately $29,000. Jain Global LLC purchased a new position in shares of Pulmonx in the third quarter worth approximately $30,000. Finally, Sei Investments Co. bought a new stake in Pulmonx during the first quarter valued at approximately $31,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Stock Performance

LUNG stock traded up $0.40 on Thursday, hitting $1.65. The company had a trading volume of 4,111,498 shares, compared to its average volume of 483,731. The company has a current ratio of 4.91, a quick ratio of 4.04 and a debt-to-equity ratio of 0.81. Pulmonx has a 12-month low of $1.13 and a 12-month high of $2.89. The stock has a market cap of $69.48 million, a price-to-earnings ratio of -1.27 and a beta of 0.30. The stock’s 50-day simple moving average is $1.41 and its 200 day simple moving average is $1.47.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. The firm had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. As a group, equities research analysts expect that Pulmonx will post -1.13 earnings per share for the current fiscal year.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.